BRUSSELS, Belgium, 5 January 2012 - 19:30 (CET) - regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 26,800 UCB shares on the Brussels stock exchange on the date and at the price indicated hereunder:
Date | Price EUR | Amount |
2/01/2012 | 32.50 | 7500 |
2/01/2012 | 32.51 | 4800 |
2/01/2012 | 32.52 | 3100 |
3/01/2012 | 32.50 | 3500 |
3/01/2012 | 32.63 | 1000 |
4/01/2012 | 32.83 | 3300 |
4/01/2012 | 32.79 | 3500 |
4/01/2012 | 32.59 | 100 |
These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company's share option plans of which the detail is given in UCB annual report.
UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, antje.witte@ucb.com
About UCB
) is a global biopharmaceutical company focused on the
discovery and development of innovative medicines and
solutions to transform the lives of people living with
severe diseases of the immune system or of the central
nervous system. With more than 8 500 people in about 40
countries, the company generated revenue of EUR 3.2 billion
in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
UCB Forward looking statements
This press release contains forward-looking statements
based on current plans, estimates and beliefs of
management. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including estimates of
revenues, operating margins, capital expenditures, cash,
other financial information, expected legal, political,
regulatory or clinical results and other such estimates and
results. By their nature, such forward-looking statements
are not guarantees of future performance and are subject to
risks, uncertainties and assumptions which could cause
actual results to differ materially from those that may be
implied by such forward-looking statements contained in
this press release. Important factors that could result in
such differences include: changes in general economic,
business and competitive conditions, the inability to
obtain necessary regulatory approvals or to obtain them on
acceptable terms, costs associated with research and
development, changes in the prospects for products in the
pipeline or under development by UCB, effects of future
judicial decisions or governmental investigations, product
liability claims, challenges to patent protection for
products or product candidates, changes in laws or
regulations, exchange rate fluctuations, changes or
uncertainties in tax laws or the administration of such
laws and hiring and retention of its employees. UCB is
providing this information as of the date of this press
release and expressly disclaims any duty to update any
information contained in this press release, either to
confirm the actual results or to report a change in its
expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
distribué par | Ce noodl a été diffusé par UCB SA et initialement mise en ligne sur le site http://www.ucb-group.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-05 20:31:26 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |